Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 16/20 | 1.00 |
| ▸ | ATF1 | P18846 | 9/20 | 1.00 |
| ▸ | JUN | P05412 | 8/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 8/20 | 1.00 |
| ▸ | RELA | Q04206 | 8/20 | 1.00 |
| ▸ | XPO1 | O14980 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8561758 | 0.88 | NFKB1 (1.00) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL1864557 | 0.88 | NFKB1 (0.78) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL1862523 | 0.78 | NFKB1 (0.74) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL13077672 | 0.77 | XPO1 (0.71) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL13077675 | 0.77 | XPO1 (0.69) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL8557809 | 0.76 | NFKB1 (0.75) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL8518174 | 0.75 | NFKB1 (0.62) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL330789 | 0.75 | P2RX1 (0.64) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL3128576 | 0.74 | NFKB1 (0.61) | NFKB1ATF1JUNNFKB2RELA | |
| SCHEMBL2307377 | 0.74 | NFKB1 (0.61) | NFKB1ATF1JUNNFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20250011425-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | UNIV TEMPLE (US) | 2025-01-09 | — | — | US | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240261333-A1 | NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | claimed |
| US-12024715-B2 | Compositions and methods for improved T cells | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-07-02 | — | — | US | claimed |
| WO-2022256620-A1 | NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY | THE BROAD INSTITUTE, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| US-20180117067-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE | 2018-05-03 | — | — | US | claimed |
| WO-2016160880-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE (US) | 2016-10-06 | — | — | WO | claimed |
| EP-1393277-B1 | USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON INC (CH) | 2006-07-19 | — | — | EP | claimed |
| EP-1542768-A1 | USE OF CYTOKINE SYNTHESIS INHIBITORS FOR THE TREATMENT OF DRY EYE DISORDERS | Alcon, Inc. (CH) | 2005-06-22 | — | — | EP | claimed |
| WO-2004098510-A2 | CYSTIC FIBROSIS THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2004026406-A1 | USE OF CYTOKINE SYNTHESIS INHIBITORS FOR THE TREATMENT OF DRY EYE DISORDERS | ALCON, INC. (CH) | 2004-04-01 | — | — | WO | claimed |
| US-20040058875-A1 | Methods of treating dry eye disorders | ALCON, INC. | 2004-03-25 | — | — | US | claimed |
| US-6696453-B2 | ADMINISTERING NF- KAPPA B INHIBITORS FOR THERAPY OF DRY EYES | ALCON, INC. (CH) | 2004-02-24 | — | — | US | claimed |
| WO-2002095704-A9 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON INC (CH) | 2003-02-27 | — | — | WO | claimed |
| US-20030008854-A1 | Use of NF-kappabeta inhibitors to treat dry eye disorders | ALCON, INC. | 2003-01-09 | — | — | US | claimed |
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2002095704-A1 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON, INC. (CH) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002086076-A2 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |